Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Maurizio Benucci, Maria Infantino & Mariangela Manfredi. (2020) Biomarkers and pharmacoeconomics in rheumatoid arthritis: a good marriage. Journal of Medical Economics 23:9, pages 923-925.
Read now
Read now
Articles from other publishers (5)
Manman Geng, Ke Xu, Liesu Meng, Jing Xu, Congshan Jiang, Yuanxu Guo, Xiaoyu Ren, Xiaowei Li, Yizhao Peng, Si Wang, Fumeng Huang, Jing Zhang, Xipeng Wang, Wenhua Zhu & Shemin Lu. (2020) Up-regulated DERL3 in fibroblast-like synoviocytes exacerbates inflammation of rheumatoid arthritis. Clinical Immunology 220, pages 108579.
Crossref
Crossref
Daniel Aletaha. (2020) Precision medicine and management of rheumatoid arthritis. Journal of Autoimmunity 110, pages 102405.
Crossref
Crossref
Lisa K. Stamp, Suz Jack Chan, Carlo Marra, Caitlin Helme & Gareth J. Treharne. (2019) Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence. Musculoskeletal Care 17:3, pages 161-169.
Crossref
Crossref
Fabrizio Cantini & Maurizio Benucci. (2019) Additional comment to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Scherlinger and Schaeverbeke. Annals of the Rheumatic Diseases 78:4, pages e25-e25.
Crossref
Crossref
Sophie Henaux, Adeline Ruyssen-Witrand, Alain Cantagrel, Thomas Barnetche, Bruno Fautrel, Nathalie Filippi, Cédric Lukas, Bernd Raffeiner, Maurizio Rossini, Yannick Degboé & Arnaud Constantin. (2018) Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Annals of the Rheumatic Diseases 77:4, pages 515-522.
Crossref
Crossref